Rapport Therapeutics, Inc.
RAPP
$11.38
$0.767.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.12M | 18.79M | 14.68M | 11.48M | 8.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.06M | 74.33M | 62.25M | 48.08M | 36.18M |
| Operating Income | -83.06M | -74.33M | -62.25M | -48.08M | -36.18M |
| Income Before Tax | -78.31M | -71.84M | -63.01M | -51.30M | -34.78M |
| Income Tax Expenses | -- | 6.00K | 7.00K | 9.00K | 10.00K |
| Earnings from Continuing Operations | -78.31 | -71.85 | -63.02 | -51.31 | -34.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.31M | -71.85M | -63.02M | -51.31M | -34.79M |
| EBIT | -83.06M | -74.33M | -62.25M | -48.08M | -36.18M |
| EBITDA | -82.22M | -73.70M | -61.82M | -47.83M | -36.07M |
| EPS Basic | -13.85 | -21.28 | -26.47 | -29.23 | -22.66 |
| Normalized Basic EPS | -6.40 | -11.01 | -14.25 | -15.97 | -13.65 |
| EPS Diluted | -13.85 | -21.28 | -26.47 | -29.23 | -22.66 |
| Normalized Diluted EPS | -6.40 | -11.01 | -14.25 | -15.97 | -13.65 |
| Average Basic Shares Outstanding | 82.64M | 49.26M | 15.93M | 6.71M | 6.02M |
| Average Diluted Shares Outstanding | 82.64M | 49.26M | 15.93M | 6.71M | 6.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |